| DC Field | Value | Language |
|---|
| dc.contributor.author | Dogot, Marta | - |
| dc.contributor.author | Popa, Ana | - |
| dc.date.accessioned | 2020-08-18T12:09:12Z | - |
| dc.date.available | 2020-08-18T12:09:12Z | - |
| dc.date.issued | 2018 | - |
| dc.identifier.citation | DOGOT, Marta, POPA, Ana. Therapy with clopidogrel based on CYP2C19 genotype. In: MedEspera: the 7th Internat. Medical Congress for Students and Young Doctors: abstract book. Chișinău: S. n., 2018, p. 99-100. | en_US |
| dc.identifier.uri | https://medespera.asr.md/wp-content/uploads/Abastract-Book-2018.pdf | - |
| dc.identifier.uri | http://repository.usmf.md/handle/20.500.12710/11416 | - |
| dc.description | Nicolae Testemitanu State University of Medicine and Pharmacy of the Republic of Moldova | en_US |
| dc.description.abstract | Introduction. Combined therapy, clopidogrel plus aspirin, prevents secondary thrombotic in
acute coronary syndromes (ACS), after percutaneous coronary interventions (PCI) with
placement of a coronary artery stent. Clopidogrel is activated in the liver by cytochrome P450
enzymes. CYP2C19 is the principal enzyme. The most common loss-of-function variant is CYP2C19*2. This contributes to the decrease in the active metabolite of clopidogrel in the blood
and reduce the effectiveness of clopidogrel therapy. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | MedEspera | en_US |
| dc.subject | CYP2C19 genotype | en_US |
| dc.subject | clopidogrel | en_US |
| dc.title | Therapy with clopidogrel based on CYP2C19 genotype | en_US |
| dc.type | Article | en_US |
| Appears in Collections: | MedEspera 2018
|
